O'Neill Gilmore Neil — SEC insider filings
SEC reporting owner CIK 1742084. 27 insider filings on record with FilingPulse; latest filed 2026-11-13.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2020-12-14 to 2026-11-13. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 13 legs across 13 filings — 189,755 shares, $1,070,556 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: sale of 77,824 shares @ $9.42 ($732,884) in Editas Medicine, Inc., filed 2024-03-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | CEO, Director | 18 | — | 13 legs · 189,755 sh · $1,070,556 | 12 |
| Unity Biotechnology, Inc. (UBX) | Director | 5 | — | — | 5 |
| Sarepta Therapeutics, Inc. (SRPT) | EVP, R&D & CMO | 2 | — | — | 4 |
| Aptinyx Inc. (APTX) | Director | 2 | — | — | 2 |
Insider filings — O'Neill Gilmore Neil
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 21,164 @ $2.42 | EDGAR |
| 2026-11-06 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 43,567 @ $0 | EDGAR |
| 2026-09-04 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 5,124 @ $3.04 | EDGAR |
| 2026-06-05 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 15,380 @ $2.70 | EDGAR |
| 2026-03-16 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 1,015,200 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 5,394 @ $2.02 | EDGAR |
| 2025-12-04 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 5,603 @ $2.15 | EDGAR |
| 2025-09-04 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 5,592 @ $2.60 | EDGAR |
| 2025-06-04 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 15,192 @ $1.72 | EDGAR |
| 2025-03-27 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 828,000 (derivative) @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 16,632 @ $1.71 | EDGAR |
| 2024-12-05 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 1,618 @ $2.08 | EDGAR |
| 2024-09-06 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 1,555 @ $3.42 | EDGAR |
| 2024-06-21 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 12,191 @ $5.50 | EDGAR |
| 2024-03-05 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 130,700 @ $0 · Grant/award (A): 72,213 @ $0 · Grant/award (A): 72,212 @ $0 · Sale (S): 77,824 @ $9.42 · Grant/award (A): 392,100 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | Editas Medicine, Inc. (EDIT) | Sale (S): 6,486 @ $9.50 | EDGAR |
| 2023-03-06 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 50,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 86,655 @ $0 · Grant/award (A): 950,209 (derivative) @ $0 | EDGAR |
| 2022-05-31 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2021-10-22 | 4 | Aptinyx Inc. (APTX) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-06-28 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 13,425 (derivative) @ $0 | EDGAR |
| 2021-03-10 | 4/A | Sarepta Therapeutics, Inc. (SRPT) | Tax withholding (F): 524 @ $86.97 · Grant/award (A): 15,000 @ $0 | EDGAR |
| 2021-03-05 | 4 | Sarepta Therapeutics, Inc. (SRPT) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2020-12-14 | 4 | Unity Biotechnology, Inc. (UBX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1742084 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs